EXPERT POINT OF VIEW: Sumanta K. Pal, MD


Get Permission

Sumanta K. Pal, MD

Sumanta K. Pal, MD

ASCO EXPERT Sumanta K. Pal, MD, of City of Hope, Duarte, California, commented, “IMmotion 151 is a positive trial and represents an important breakthrough. We have debated combination treatment strategies for advanced kidney cancer. This study looks at the combination of a programmed cell death ligand 1 (PD-L1) inhibitor plus an anti–vascular endothelial growth factor agent and shows a higher response rate compared with sunitinib (Sutent). Complete response represents the highest bar, and this is where we will hang our hats. Complete response rates were 9% for the combination and 5% for sunitinib in the PD-L1–positive patients, and 5% and 2%, respectively, in the intent-to-treat treat analysis.”

He continued: “Tolerability is an important piece of the puzzle. The big difference in this trial centers on toxicity and tips the scales toward atezolizumab (Tecentriq) plus bevacizumab (Avastin). The side-effect profile compares favorably with nivolumab (Opdivo) plus ipilimumab (Yervoy), another combination studied in newly diagnosed patients. With nivolumab/ipilimumab, 60% of patients required steroids for immune-related side effects vs 16% of patients in this trial.”

Dr. Pal added, “Progression-free survival was consistently improved with the combination of atezolizumab plus bevacizumab over sunitinib in both the PD-L1–positive patients and the intent-to-treat analysis. This may allow us to get away from using PD-L1 status for triaging patients.”

When asked whether the cost of using two expensive drugs was justifiable, Dr. Pal said, “There was a compelling trend toward overall survival improvement with atezolizumab/bevacizumab, and for any benefit in overall survival, the cost is justifiable.” ■

DISCLOSURE: Dr. Pal reported no conflicts of interest.


Related Articles

Atezolizumab Plus Bevacizumab Improves Progression-Free Survival in First-Line Treatment of Advanced Renal Cell Carcinoma

THE TYROSINE KINASE inhibitor sunitinib (Sutent) has been the mainstay of treatment for first-line treatment of advanced renal cell carcinoma for about a decade. The IMmotion151 study reported at the 2018 Genitourinary Cancers Symposium found that the combination of the immune checkpoint inhibitor...

Advertisement

Advertisement

Advertisement

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.